Tacrolimus ointment: A review of its therapeutic potential as a topical therapy in atopic dermatitis

American Journal of Clinical Dermatology

Volumn 2, Issue 6, 2001, Pages 389-406

  Cheer, S M ^a   Plosker, G L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ANTIGEN PRESENTING CELL; ATOPIC DERMATITIS; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; PRIORITY JOURNAL; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0035664122     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200102060-00005     Document Type: Review

References (112)

1. Atopic dermatitis: Immunobiology and treatment with immune modulators
2. Atopic dermatitis
3. Allergic and immunologic skin disorders
4. Novel immunomodulators for topical skin disease therapy
5. Pathogenesis of atopic dermatitis
6. Cellular and immunologic mechanisms in atopic dermatitis
7. Atopic dermatitis
8. Atopic dermatitis: From the genes to skin lesions
9. Human basophil releasability. II. Changes in basophil releasability in patients with atopic dermatitis
10. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis
11. Studies of hypersensitivity reactions to foods in infants and children
12. Role of immediate hypersensitivity in the pathogenesis of atopic dermatitis
13. Increased plasma histamine concentrations after food challenges in children with atopic dermatitis
14. Food hypersensitivity and atopic dermatitis: Evaluation of 113 patients
15. Immunopathology of atopic dermatitis
16. Atopic dermatitis
17. Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon-gamma
18. + memory T cells are activated in atopic dermatitis and regulate IgE by an IL-13-dominated cytokine pattern: IgG4 counter-regulation by CLA memory T cells
19. Immunoglobulin E and immunoglobulin G subclass distribution in vivo and relationship to in vitro generation of interferon-gamma and neopterin in patients with severe atopic dermatitis
20. Decreased interferon gamma and increased interleukin-4 production in atopic dermatitis promotes IgE synthesis
21. Skin-derived aeroallergen-specific T-cell clones of the TH2 phenotype in patients with atopic dermatitis
22. + allergen-specific T lymphocytes in atopic dermatitis lesional skin
23. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis
24. Biochemical and immunologic mechanisms in atopic dermatitis: New targets for emerging therapies
25. Assembling the puzzle pieces in atopic inflammation
26. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells
27. + T-cell infiltration with increased IL-16 gene expression in atopic dermatitis
28. In vivo expression of IL-12 and IL-13 in atopic dermatitis
29. Granulocyte macrophage colony-stimulating factor contributes to enhanced monocyte survival in chronic atopic dermatitis
30. Atopic dermatitis: Recent trends in pathogenesis and therapy
31. FcεRI-expressing antigen-presenting cells: New players in the atopic game
32. Allergen presentation by epidermal Langerhans' cells from patients with atopic dermatitis is mediated by IgE
33. Tacrolimus: A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation
34. Tacrolimus: An update of its pharmacology and clinical efficacy in the management of organ transplantation
35. Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation
36. Topical tacrolimus (FK 506): A new milestone in the management of atopic dermatitis
37. Immunosuppressive macrolides of the type FK 506: A novel class of topical agents for treatment of skin diseases?
38. Anti-inflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis
39. Topical FK506: Suppression of allergic and irritant contact dermatitis in the guinea pig
40. Inhibition of contact allergy reactions by topical FK506
41. Mode of action of tacrolimus (FK506): Molecular and cellular mechanisms
42. Tacrolimus (FK506): Experience in dermatology
43. Treatment of atopic dermatitis: Role of tacrolimus ointment as a topical noncorticosteroidal therapy
44. Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid
45. Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses
46. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506)
47. Topical triamcinolone and tacrolimus differ in their in vivo effects on Langerhan's cells during the treatment of atopic dermatitis
48. Anti-inflammatory effect of FK-506 on human skin mast cells
49. 1
50. Antiinflammatory effect of FK 506 on human basophils
51. Inhibition of in vitro histamine release (HR) from human basophils by the immunosuppressive drug FK506
52. Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation
53. Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells
54. Tacrolimus induces increased expression of transforming growth factor-β1 in mammalian lymphoid as well as nonlymphoid cells
55. Immunomorphological and ultrastructural characterisation of langerhans cells and a novel inflammatory dindritic epidermal cell (IDEC) population in lesional skin of atopic eczema
56. Tacrolimus ointment for atopic dermatitis
57. + cells
58. Tacrolimus: The drug for the turn of the millennium?
59. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin
60. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial
61. Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (Fk506)
62. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions
63. Tacrolimus (FK506) ointment for atopic dermatitis: A phase I study in adults and children
64. A short-term trial of tacrolimus ointment for atopic dermatitis
65. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy
66. Early phase II study of FK506 ointment on atopic dermatitis
67. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children
68. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients
69. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis
70. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children
71. Long-term study of FK506 (tacrolimus) ointment in patients with atopic dermatitis: Analysis at the time of completion of 2-year observation
72. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis
73. Comparative study of FK506(tacrolimus) ointment vs. alclometasone dipropionate ointment in atopic dermatitis (face and neck lesions)
74. Tacrolimus - Winning the battle against atopic dermatitis
75. A long-term noncomparative trial to evaluate the safety of topically applied tacrolimus as treatment of atopic dermatitis in pediatric patients
76. Long-term study of FK506 (tacrolimus) ointment in patients with atopic dermatitis: Analysis at the time of 1 year observation
77. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, safety
78. Old, new, and emerging therapies for atopic dermatitis
79. Current management and therapy of atopic dermatitis
80. Cyclosporin in atopic dermatitis
81. Four decades of topical corticosteroid assessment
82. Skin atrophy induced by initial continuous topical application of clobetasol followed by intermittent application
83. Adverse effects of topical corticosteroids
84. Update on therapy of atopic dermatitis
85. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis
86. Antipruritic effect of oral cyclosporin A in atopic dermatitis
87. Cyclosporin in atopic dermatitis: A multicentre placebo-controlled study
88. Cyclosporine in the treatment of dermatologic disease: An update
89. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: Nestedcohort crossover study
90. Use of the newer immunosuppressive agents in dermatology
91. Topical cyclosporin for psoriasis: In vitro skin penetration and clinical study
92. Topical cyclosporine and contact dermatitis in guinea pig and man
93. Topical cyclosporin A in psoriasis
94. Atopic dermatitis and SDZ ASM 981: Setting the scene
95. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis
96. SDZ ASM 981: A new approach to the management of atopic dermatiis
97. Protopic pediatric lymphoma tracking recommended in phase IV studies
98. Atopic dermatitis: The burden on patients and society
99. Quality of life measurement in dermatology: A practical guide